Study to Evaluate Broadlumab vs Placebo and Ustekinumab

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708629

Plaque Psoriasis

TERMINATED PHASE3

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603

Moderate to Severe Plaque Psoriasis

TERMINATED PHASE3

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab

NCT04533737

Plaque Psoriasis Psoriasis Vulgaris Psoriasis

TERMINATED PHASE4

Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

NCT04305327

Psoriasis

TERMINATED PHASE3

A Phase 4 Clinical Study of Brodalumab

NCT04183881

Psoriasis Vulgaris Psoriatic Arthritis Pustular; Psoriasis, Palmaris Et Plantaris +1 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is up to 5 years. If you qualify, you will be randomized into 1 of 4 groups. Two groups will get brodalumab(1 group will get 210milligrams of brodalumab at each dose and the other group will get 140 milligrams of brodalumab at each dose), one group will get ustekinumab, and one group will get placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

210mg Brodalumab

Administered by subcutaneous injection until Week 12

Group Type EXPERIMENTAL

210mg Brodalumab

Intervention Type BIOLOGICAL

Brodalumab 210mg administered subcutaneously

140mg Brodalumab

Administered subcutaneous injection until Week 12

Group Type EXPERIMENTAL

210mg Brodalumab

Intervention Type BIOLOGICAL

Brodalumab 210mg administered subcutaneously

Ustekinumab

Administered subcutaneous injection until Week 52

Group Type ACTIVE_COMPARATOR

140mg Brodalumab

Intervention Type BIOLOGICAL

Brodalumab 140mg administered subcutaneously

Placebo

Administered subcutaneous injection until Week 12

Group Type PLACEBO_COMPARATOR

210mg Brodalumab

Intervention Type BIOLOGICAL

Brodalumab 210mg administered subcutaneously

Ustekinumab

Intervention Type BIOLOGICAL

Ustekinumab 45mg or 90mg adminstered subcutaneously

Placebo

Intervention Type BIOLOGICAL

Placebo administered subcutaneously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

210mg Brodalumab

Brodalumab 210mg administered subcutaneously

Intervention Type BIOLOGICAL

140mg Brodalumab

Brodalumab 140mg administered subcutaneously

Intervention Type BIOLOGICAL

Ustekinumab

Ustekinumab 45mg or 90mg adminstered subcutaneously

Intervention Type BIOLOGICAL

Placebo

Placebo administered subcutaneously

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has had stable moderate to severe plaque psoriasis for at least 6 months before first dose of IP.
* Subject has involved body surface area \>\_10%, PASI\>\_, and sPGA\>\_3 at screening and at baseline.
* For women, a negative serum pregnancy test during screening a negative urine pregnancy test at baseline.
* Subject has no known history of active tuberculosis.
* Subject has a negative test for tuberculosis during screening.

Exclusion Criteria

* Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at the time of the screening visit that would interfere with evaluations of the effect of IP on psoriasis.
* Subject has a planned surgical intervention between baseline and the week 52 evaluation.
* Subject an active infection or history of infections.
* Subject has any systemic disease considered by the investigator to be clinically significant and uncontrolled.
* Subject has known history of Crohn's disease.
* Subject has known history of hepatitis B, hepatitis C, or human immunodeficiency virus.
* Subject had myocardial infarction or unstable angina pectoris within the past 12 months prior to the first dose of IP.
* Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.
* Subject has history of malignancy within 5 years EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma.
* Subject has received live vaccine(s) within 28 days of the first dose of IP.
* Subject has used ustekinumab and/or antio-IL-17 biologic therapy ever or other experimental or commercially available biologi immune modulator(s) within 12weeks prior to the first IP dose
* Subject currently is enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s).
* For women not willing to use highly effective methods of birth control during treatment and for 15 weeks after the last dose.
* For women; pregnant or breast feeding, or planning to become pregnant while enrolled in the study and for 15 weeks after the last dose.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes